66 results about "Respiration Disorders" patented technology

Intranasal dry powder epinephrine compositions are described herein. The compositions include epinephrine or a pharmaceutically acceptable salt thereof, as well as a stabilizing agent and a carrier. The stabilizing agent is operable to include citric acid, or a pharmaceutically acceptable salt derived therefrom. Such intranasal compositions as described herein are useful in the treatment of health conditions which threaten the central nervous system (CNS) and impede the actions of alpha and beta-adrenergic receptors. Such health conditions include anaphylaxis, bronchospasms, respiratory impairment, organophosphate poisoning, and major adverse cardiac events (MACE).

The invention discloses application of tannin compounds in preparation of drugs for resisting porcine reproductive and respiratory disorder viruses. The inventor of the invention performs activity screening on natural tannin compounds, and finds that the tannin compounds as shown in the formula 1 have excellent anti-PRRSV activity, and the EC50 value of the tannin compounds to PRRSV is lower than or obviously lower than that of ribavirin; therefore, the inhibiting effect of the compounds on the PRRSV is greater than or even far greater than that of a positive control drug ribavirin. The compounds have an unexpected effect of resisting PRRSV (porcine reproductive and respiratory syndrome virus).

The invention relates to a voiceprint recognition method and device under an encircling type signal domain and man-machine interaction equipment, and belongs to the technical field of wearable device.The method comprises the steps that voice signals of a target user are collected, and physiological signals at least including wrist movement acceleration, skin surface vibration frequency and blood oxygen saturation are synchronously obtained; carrying out environmental noise separation processing on the voice signal, and extracting a fundamental frequency jitter rate and a voiceprint feature vector of a formant migration track contained in the voice signal; performing time-frequency transformation on the physiological signal, and performing feature fusion on the physiological signal and a voiceprint feature vector to generate a feature map containing a user identity identifier and a physiological state parameter; and event judgment is carried out on the voice feature segment and the physiological feature segment in the feature map, so that the voiceprint recognition precision is improved in a complex environment, and meanwhile, the real-time early warning effect of user identity determination and physiological abnormalities such as respiratory disorder is realized.

The present disclosure describes systems and methods for assessing heart and respiratory disorders in a patient using a video analysis tool to analyze video data taken of the patients neck region. The video analysis tool allows for an accurate, objective assessment of the patient. In some aspects of the present disclosure, a clinician may capture video data of the patients neck region and run the video analysis tool. Additionally or alternatively, the system may be implemented remotely whereby the video analysis tool may be executed remotely from the video recording device. The video analysis tool extracts pulsatile signals in the neck region from the video data and determines pulsatile signals of interest for assessing heart and respiratory disorders in the patient. The video analysis tool generates assessment data based on the pulsatile signals of interest.

Examples of the disclosure include a system for treating disordered breathing in a patient, including an electrical-pulse generator (IPG) to generate an electrical stimulation and including a controller and a power source, a lead including a first sensor, and a second sensor, the controller being configured to provide, via the lead, first electrical stimulation to a target nerve including a phrenic nerve, receive, from the lead, respiratory information indicative of a respiratory parameter of the patient, determine, based on the respiratory information, a therapy-specific indicator indicative of an effect of the stimulation, receive, from the at least one second sensor, non-respiratory information, determine, based on the non-respiratory information, a patient-specific indicator relating to at least one patient condition, modify, based on at least one of the indicators, at least one parameter of the stimulation, and provide, via the lead, at least one second electrical stimulation having the modified parameter.

The utility model discloses an airway protection device, relates to the technical field of oral cavity nursing, and aims to solve the problem that the operation process is relatively tedious due to the fact that medical personnel need to manually support a trachea cannula besides the traditional mouth gag for opening the oral cavity when the existing respiratory disorder patient is subjected to oral cavity nursing. Comprising a U-shaped limiting connecting rod; the external expansion handles are installed at the two ends of the U-shaped limiting connecting rod, side arms are installed on one sides of the inner walls of the external expansion handles, and clamping pieces are installed on the inner sides of the side arms; the support is installed on the outer wall of the side arm on one side, a C-shaped buckle is installed at one end of the support, an air bag is installed on the inner wall of the C-shaped buckle, an air inflation pipe is installed on the outer wall of the air bag, an air inflation pressurization ball is installed at one end of the air inflation pipe, and an air inflation valve is installed at the joint of the air inflation pressurization ball and the air inflation pipe.

The application discloses a mixed preparation for preventing and treating porcine reproductive and respiratory syndrome virus (PRRSV) infection, a preparation method and application thereof, and belongs to the technical field of biological and animal epidemic disease prevention and treatment. The application provides a mixed preparation for preventing and treating PRRSV infection, a preparation method and application thereof, and sequences of two strains of nanobodies and pig IgG1 Fc contained in the mixed preparation, and in-vivo anti-PRRSV infection activity of the mixed preparation is evaluated. The mixed preparation is applied to prevention and treatment of PRRSV infected pigs, and provides a new strategy and preparation for development of a therapeutic drug for the disease, and has a good market application prospect.

An apparatus for treating respiratory disorders in a patient is disclosed. The apparatus includes a pressure generator configured to deliver a flow of air at positive pressure through a patient interface to an airway of the patient, a sensor configured to generate a signal representative of a respiratory flow of the patient, and a controller. And a controller configured to control the pressure generator to deliver a ventilation therapy with a base pressure and pressure support through the patient interface, an apnea being detected from the signal representative of a respiratory flow of the patient, controlling the pressure generator to deliver one or more detected breaths to the patient during the apnea, determining patency of the airway of the patient from a waveform of the respiratory flow signal responsive to one of the one or more detected breaths, an effective duration of the apnea is calculated based on the patency of the airway, and a setpoint of the base pressure for the ventilation therapy is adjusted in response to the apnea based on the effective duration of the apnea.

A respiratory pressure therapy (RPT) system may be configured to direct a flow of air to a therapeutic pressure above atmospheric pressure to a patient interface worn by a patient to treat a respiratory disorder The RPT system may include: a component that at least partly forms a passage for the flow of air at the therapeutic pressure, the component being one of the patient interface, a flow generator including a blower, an air circuit, or a humidifier; and a vaporization device that includes: a vaporization module including a vaporizer and a heating element; and a reservoir attached to the vaporization module, and the reservoir being configured to store water and provide water to the vaporizer for vaporization during use, wherein at least a portion of the vaporizer is exposed to the passage for the flow of air at the therapeutic pressure.

The invention relates to the technical field of respiratory system disease diagnosis, in particular to a respiratory disorder onset risk prediction method and system. By combining the multiple groups of indexes, early-stage evaluation can be effectively carried out on the respiratory disorder onset risk, and the obstructive respiratory arrest probability and the onset degree can be more intuitively determined through score data, so that the overall automatic prediction of respiratory disorder onset is realized.

The present invention provides the use of silencing the ECM1 gene in resisting PRRSV infection, belonging to the field of medical technology. The present invention provides the use of a reagent that affects the expression level of the ECM1 gene in the preparation of a medicament for regulating PRRSV infection in animals, as well as an siRNA that inhibits porcine reproductive and respiratory syndrome virus infection in animals. After the present invention used two siRNAs to interfere with ZMAC-4 cells respectively, the expression of ECM1 and PRRSV-ORF6 in the cells transfected with siRNA was significantly reduced, indicating that interfering with the expression of the ECM1 gene has an inhibitory effect on PRRSV infection of ZMAC-4 cells.

The application provides a respiratory disorder evaluation system and method based on non-contact electrocardio, wherein the system comprises a non-contact electrocardio acquisition device, a non-contact electrocardio signal quality evaluation module, a respiratory signal low-frequency energy threshold discrimination module and a non-contact electrocardio respiratory signal extraction and respiratory disorder evaluation module. The system can acquire the electrocardio and respiratory coupling signal of a patient through a layer of clothes. Compared with the traditional contact wet electrode measurement method, the non-contact measurement method has the advantages of long-term monitoring and high comfort. The signal characteristics can be extracted according to the characteristics of the non-contact electrocardio signal, and the method has the advantage of high accuracy. The method uses different respiratory signal extraction methods for two cases. After the respiratory signal extraction is completed, the respiratory disorder event is judged. Based on the characteristics of the non-contact electrocardio, the signal processing related tasks can be efficiently and accurately completed.

A patient interface for treating a patient with a respiratory disorder includes: an RPT device including an electrically powered blower configured to generate pressurized breathable air; a user interface structure configured to engage against the patient's face, the user interface structure at least partially forming an inflation chamber, the inflation chamber configured to receive the pressurized breathable air; a head-mounted interface configured to substantially cover an eye of the patient; a flow generator housing at least partially enclosing the head mounted interface and the motorized blower and connected to the plenum, the flow generator housing including at least one air opening to receive ambient air for delivery to the RPT device; and a positioning and stabilizing structure configured to maintain the user interface structure in a therapeutically effective position.

In certain example embodiments, a system and / or method of guiding transitions between therapy modes in connection with the treatment and / or diagnosis of a patient for a respiratory disorder is / are provided. Respiratory disorder treatment according to a first therapy mode is provided. Input indicating a second therapy mode to be transitioned to following provision of the first therapy mode is received, with the second therapy mode being different from the first therapy mode. At least one default treatment parameter suitable for the second therapy mode is assigned or calculated. Each default treatment parameter of the second therapy mode is presented, with each default treatment parameter being adjustable by an operator during the presenting. Transitioning from the first therapy mode to the second therapy mode is performed by providing respiratory disorder treatment in accordance with the second therapy mode and each default treatment parameter and any adjustments made thereto prior to the transitioning. Advantageously, the chances of a patient being disturbed by transitioning from mode-to-mode are reduced.

The present invention discloses the application of siRNA targeting the mGluR2 gene, monoclonal antibodies against the extracellular domain of the protein encoded by the mGluR2 gene, truncated peptides containing the extracellular domain of the protein encoded by the mGluR2 gene, or recombinant vectors containing the gRNA gene sequence targeting the mGluR2 gene and the CAS9 protein gene sequence in the preparation of preparations for inhibiting influenza virus, swine acute diarrhea syndrome coronavirus, porcine epidemic diarrhea virus, Japanese encephalitis virus, and porcine reproductive and respiratory syndrome virus. The present invention also discloses the application of a genetic engineering operation method for knocking out the mGluR2 gene in the preparation of a new mouse strain with enhanced influenza resistance. The aforementioned applications have prospects for promotion.

The invention provides a method and device for carrying out safety evaluation on an airway measurement value and application, and relates to the technical field of medical data processing. The method comprises the following steps: acquiring an airway measurement value of a respiratory disorder patient in a corresponding diagnosis and treatment stage; according to the diagnosis and treatment stage of the respiratory disorder patient, the airway measurement value is evaluated and managed; the evaluation management comprises the following steps: selecting key airway measurement values from the airway measurement values of the diagnosis and treatment stage; the key airway measurement value is correspondingly provided with a respiration evaluation index; wherein the respiration evaluation indexes comprise an oxygenation state index and an airway smoothness index; and configuring an airway safety management scheme of the respiratory disorder patient in the corresponding diagnosis and treatment stage according to the key airway measurement value and the corresponding respiration evaluation index. The airway measurement values of the respiratory disorder patient in different diagnosis and treatment stages can be monitored, the key airway measurement value is selected from the airway measurement values and used for evaluating the airway safety condition of the respiratory disorder patient in the corresponding diagnosis and treatment stage, and then medical staff can conveniently ensure the airway safety of the respiratory disorder patient according to a corresponding airway safety management scheme.

The invention discloses application of siRNA (small interfering Ribonucleic Acid) of a targeted mGluR2 gene, a monoclonal antibody for resisting an extracellular domain of a protein coded by the mGluR2 gene, a truncated peptide containing the extracellular domain of the protein coded by the mGluR2 gene or a recombinant vector containing a gRNA (guide Ribonucleic Acid) gene sequence and a CAS9 protein gene sequence of the targeted mGluR2 gene in preparation of a medicine for inhibiting influenza virus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute diarrhea syndrome coronavirus, swine acute The invention also relates to application of the compound in preparations for treating porcine epidemic diarrhea virus, Japanese encephalitis virus and porcine reproductive and respiratory syndrome virus. The invention also discloses an application of the gene engineering operation method for knocking out the mGluR2 gene in preparation of a new mouse strain for improving influenza resistance. The application has a popularization prospect.

To provide a medical device for screening, diagnosis, monitoring, amelioration, treatment or prevention of respiratory disorders having one or more of improved comfort, cost, efficacy, ease of use and manufacturability.SOLUTION: A patient interface is provided which includes: a plenum chamber pressurizable to a therapeutic pressure, the plenum chamber comprising two plenum chamber connectors; a seal-forming structure arranged to seal with a region of a patient's face; a positioning and stabilizing structure comprising two conduits each configured to connect to a corresponding one of the plenum chamber connectors; a vent assembly having a plurality of vent holes configured to allow a continuous flow of gases exhaled by the patient from within the plenum chamber to ambience throughout the patient's respiratory cycle; and a heat and moisture exchanger (HMX) assembly including an HMX frame and a material that is supported by the HMX frame such that the flow of air entering the plenum chamber from the plenum chamber connectors passes through the material before entering the patient's airways.SELECTED DRAWING: Figure 57

This invention relates to the field of sleep monitoring data fusion processing technology, and discloses a sleep monitoring method based on the fusion of non-invasive brain oxygen saturation (AHI) and multiple physiological parameters. The method includes: S1, simultaneously acquiring multiple physiological parameter signals during the subject's sleep; S2, extracting and analyzing the AHI signal to generate multiple characterization markers; S3, identifying respiratory events related to the subject's apnea information from the respiratory signal and pulse oximetry signal, calculating the apnea-hypopnea index (AHI); and performing correlation analysis on the identified respiratory events and multiple characterization markers to calculate a correlation coefficient; S4, obtaining a comprehensive sleep monitoring assessment report based on the correlation coefficient and the AHI to determine the severity of the subject's current respiratory disturbance and the risk of brain tissue hypoxia. By improving the effectiveness of AHI in non-invasive brain oxygen saturation monitoring, the confirmatory nature of non-invasive brain oxygen saturation information in the respiratory correlation diagnosis during sleep monitoring is ensured.

The present invention relates to a process for the preparation of a pharmaceutical dosage form comprising effective and selective TASK-1 and / or TASK-3 channel inhibitors, and the use of the dosage form obtained by said process for the treatment and / or prevention of respiratory disorders, including sleep-related respiratory disorders, such as obstructive and central sleep apnea and snoring.

The present invention relates to devices with power source connections for treating respiratory disorders. Respiratory devices, such as ventilators, for use in treating respiratory disorders and for preventing respiratory disorders are configured to be powered from a number of different power sources including an internal battery, an external battery, an alternating current power source, or a direct current power source. The device can be electrically connected to a plurality of external batteries in a string, and power from each external battery is used in turn along the string. A controller of the respiratory device is configured to detect the connection of the different power sources, and control the use of the different power sources using a power priority scheme. The controller can determine an estimate of the total available battery capacity from all electrically connected batteries, and display the total battery capacity on a user interface display of the device.

The invention relates to an alcohol-free, high-lasting ambient fragrance. Since the ambient fragrance of the invention, containing the natural ingredient, does not contain alcohol, said fragrance can be easily used by the individuals suffering from migraine and respiratory disorders.

The invention relates to metered dose inhaler comprising a stable pharmaceutical composition of fluticasone or its pharmaceutically acceptable ester contained in a canister fitted with a metering valve, an actuator and dose counter. The invention also relates to a process for preparing said pharmaceutical composition and its use in the treatment of respiratory disorders such as asthma in a subject (e.g., a human).

To provide a medical device for diagnosis, improvement, treatment, or prevention of a respiratory disturbance, having one or more of improved comfort, cost, effectiveness, usability, and manufacturability.SOLUTION: An aspect of the present technology includes a positioning and stabilizing structure for holding a seal formation structure at a therapeutically effective position of the head of a patient. The seal formation structure forms a seal with the face of the patient to seal and deliver an air flow at a therapeutic pressure higher than an ambient air pressure at least by 4 cmH2O in an entire respiratory cycle of the patient when in use. The positioning and stabilizing structure includes a front hoop arranged to come in contact with an area above the upper ear bottom point of the head of the patient when in use, and a rear strap. The positioning and stabilizing structure includes an adjustment mechanism for adjusting the front hoop and the rear strap relative to the head of the patient. The adjustment mechanism is arranged by a single operation for adjusting both the front hoop and the rear strap, and fitting the positioning and the stabilizing structure to the head of different sizes.SELECTED DRAWING: Figure 25A

The invention belongs to the technical field of veterinary biological products, and particularly relates to a porcine reproductive and respiratory syndrome NADC30-like attenuated mutant strain and application thereof. The invention provides a porcine reproductive and respiratory syndrome NADC30-like attenuated mutant strain, namely an attenuated mutant strain AHFY F140 obtained by continuously transmitting a porcine reproductive and respiratory syndrome NADC30-like virulent AHFY strain on a Mac145 cell for 160 generations for attenuation, and the strain is high in proliferation capacity, good in safety and immune efficacy, and capable of being used for preparing a porcine reproductive and respiratory syndrome NADC30-like attenuated mutant strain for treating the porcine reproductive and respiratory syndrome NADC30-like virulent AHFY strain for treating the porcine reproductive and respiratory syndrome NADC30-like virulent AHFY. The prepared live vaccine can effectively prevent the porcine reproductive and respiratory syndrome caused by infection of the NADC30-liked strain on pigs. The vaccine provided by the invention has the advantages of fast immune efficacy generation, long protection period and the like, and can obviously shorten the immune blank area, reduce the immune frequency and improve the economic benefit.

The invention provides application of a silent ECM1 gene in resisting PRRSV infection, and belongs to the technical field of medicines. The invention provides application of a reagent influencing ECM1 gene expression quantity in preparation of a medicament for regulating and controlling PRRSV (porcine reproductive and respiratory syndrome virus) infected animals and siRNA (small interfering Ribonucleic Acid) for inhibiting the PRRSV infected animals. According to the invention, two kinds of siRNAs are respectively used for interfering with ZMAC-4 cells, and the expression of ECM1 and PRRSV-ORF6 in cells transfected with siRNAs is obviously reduced, which indicates that the interference of the expression of the ECM1 gene has an inhibition effect on the PRRSV infected ZMAC-4 cells.

Apparatus for treating a respiratory disorder in a patient comprises a pressure generator configured to deliver a flow of air at positive pressure to an airway of the patient through a patient interface, a sensor configured to generate a respiratory flow rate signal of the patient, and a controller. The controller may be configured to control the generator to deliver ventilation therapy having a base pressure and a pressure support through the patient interface, detect an apnea from the signal representative of respiratory flow rate of the patient, control the generator to deliver one or more probe breaths to the patient during the apnea, determine patency of the patient's airway from a waveform of the respiratory flow rate signal in response to one of the one or more probe breaths and adjust a set point for pressure of the ventilation therapy in response to the apnea.

This technology relates to a forehead cooling system configured for use with a patient interface to assist in the treatment of sleep and respiratory disorders. Embodiments of this technology include fluid cooling systems such as air cooling and water cooling. Other embodiments utilize phase change materials and thermoelectric coolers. In some embodiments, the forehead cooling system may be mounted on a positioning and stabilization structure.

The invention relates to the technical field of immune compositions, in particular to an NADC30, NADC34 and GP5 immune composition and application thereof. The immune composition comprises an NADC30 pedigree inactivated strain of the PRRSV, an NADC34 pedigree inactivated strain of the PRRSV and a GP5 protein of the PRRSV. The immune composition of NADC30, NADC34 and GP5 is obtained through research, has a remarkably high immune protection effect on pigs, can effectively reduce the morbidity of the porcine reproductive and respiratory syndrome and reduce the cost of the pig raising industry, and has important value in the pig raising industry.

The present disclosure provides methods of treating patients having a respiratory disorder, methods of identifying subjects having an increased risk of developing a respiratory disorder, and methods of detecting human Arachidonate 15-Lipoxygenase (ALOX15) variant nucleic acid molecules and variant polypeptides.